Dr. Reddy's Laboratories (RDY) free cash flow
Dr. Reddy's Laboratories (RDY) generated free cash flow of ₹18.33B in fiscal 2026 (the year ended March 31, 2026). That is 52.4% higher than the ₹12.03B of fiscal 2025. Figures as of 18 Nov 2026, 12:43 UTC, from Yahoo Finance.
Key facts
- Free cash flow, fiscal 2026
- ₹18.33B
- Change on fiscal 2025
- +52.4%
- Highest on record
- ₹40.01Bfiscal 2023
- Lowest on record
- ₹12.03Bfiscal 2025
- Fiscal years on record
- 42023–2026
Figures as of . Statements from Yahoo Finance. Amounts are in INR. Figures, not advice.
Dr. Reddy's Laboratories free cash flow, in more detail
Across the 4 fiscal years on record (2023–2026), the highest was ₹40.01B in fiscal 2023 and the lowest ₹12.03B in fiscal 2025.
Free cash flow by fiscal year
Dr. Reddy's Laboratories free cash flow, year by year
| Fiscal year | Free cash flow | Change | Year ended |
|---|---|---|---|
| 2026 | ₹18.33B | 52.4% up | |
| 2025 | ₹12.03B | 33.2% down | |
| 2024 | ₹18.00B | 55.0% down | |
| 2023 | ₹40.01B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.
How to read it
It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.
Free cash flow at health care companies of similar size
| Company | Free cash flow | Fiscal year |
|---|---|---|
| Smith & Nephew SNN | $852.00M | 2025 |
| Penumbra PEN | $174.93M | 2025 |
| Dr. Reddy's Laboratories RDY | ₹18.33B | 2026 |
| Align Technology ALGN | $490.78M | 2025 |
| Cooper Companies COO | $433.70M | 2025 |
| Fresenius Medical Care FMS | €1.77B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Dr. Reddy's Laboratories, figure by figure
- Dr. Reddy's Laboratories market cap
- Dr. Reddy's Laboratories revenue
- Dr. Reddy's Laboratories earnings
- Dr. Reddy's Laboratories earnings per share (EPS)
- Dr. Reddy's Laboratories P/E ratio
- Dr. Reddy's Laboratories P/S ratio
- Dr. Reddy's Laboratories P/B ratio
- Dr. Reddy's Laboratories operating margin
- Dr. Reddy's Laboratories dividend
- Dr. Reddy's Laboratories shares outstanding
- Dr. Reddy's Laboratories total debt
- Dr. Reddy's Laboratories cash on hand
- Dr. Reddy's Laboratories total assets
- Dr. Reddy's Laboratories return on equity (ROE)
- Dr. Reddy's Laboratories return on invested capital (ROIC)
Dr. Reddy's Laboratories (RDY) overview: price, valuation and scorecardAll health care companies by market value
Dr. Reddy's Laboratories free cash flow: questions and answers
What is Dr. Reddy's Laboratories's free cash flow?
Dr. Reddy's Laboratories (RDY) generated free cash flow of ₹18.33B in fiscal 2026 (the year ended March 31, 2026). That is 52.4% higher than the ₹12.03B of fiscal 2025.
What are the highest and lowest free cash flow figures on record for Dr. Reddy's Laboratories?
Across the 4 fiscal years on record (2023–2026), the highest was ₹40.01B in fiscal 2023 and the lowest ₹12.03B in fiscal 2025.
How is Dr. Reddy's Laboratories's free cash flow calculated?
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Dr. Reddy's Laboratories it is on record here for 4 fiscal years, 2023 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: free cash flow
All stocks guides →- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
- How a DCF valuation works, and why inputs swing it
A discounted cash flow (DCF) valuation estimates what a business is worth today by forecasting the cash it will produce and discounting each year's cash back at a required rate of return. Because most of the value lies far in the future, a one-point change in growth or discount rate can move the answer by a quarter.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Dr. Reddy's Laboratories (RDY) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/RDY/free-cash-flow
Underlying data: Yahoo Finance.